Changchun High-Tech Industry (Group) Co., Ltd.: Business Overview, Financials & Competitive Analysis
Changchun High-Tech Industry (Group) Co., Ltd. scores 6/10 on the AskCyborg Cyborg Score (Solid). Established Chinese biopharma with stable dividends and innovation focus, suitable for conservative growth investors seeking domestic pharma exposure. Changchun High-Tech demonstrates solid fundamentals as an established biopharmaceutical player with 30+ years of operational history and strong market position in China. However, exposure to domestic market concentration.
What is Changchun High-Tech Industry (Group) Co., Ltd.'s industry? Changchun High-Tech Industry (Group) Co., Ltd. operates in Biopharmaceuticals & Pharmaceutical Manufacturing. AskCyborg classifies Changchun High-Tech Industry (Group) Co., Ltd. under Biopharmaceuticals & Pharmaceutical Manufacturing in its company registry.
Changchun High-Tech Industry is a Chinese biopharmaceutical company that researches, develops, manufactures, and sells biopharmaceuticals and traditional Chinese medicines. Founded in 1993 and listed on the Shenzhen S...
Cyborg Score thesis
Established Chinese biopharma with stable dividends and innovation focus, suitable for conservative growth investors seeking...
Read the full analyst-debate transcript →Get the Latest Changchun High-Tech Industry (Group) Co., Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeChangchun High-Tech Industry (Group) Co., Ltd. Overview
Pro stress-test →Changchun High-Tech Industry is a Chinese biopharmaceutical company that researches, develops, manufactures, and sells biopharmaceuticals and traditional Chinese medicines. Founded in 1993 and listed on the Shenzhen Stock Exchange since 1996, the company operates across genetic engineering pharmaceuticals, biological vaccines, and modern Chinese medicines.
Strategic Profile
Pro stress-test →The company positions itself as a technology-driven pharmaceutical innovator with focus on biopharmaceutical products including recombinant growth hormones, vaccines, and antibody drugs. It has diversified into real estate development to supplement core pharmaceutical operations and maintains a strong dividend policy with yields around 4%.
Competitive Landscape
Pro stress-test →Changchun High-Tech competes in China's biopharmaceutical sector against both domestic players and international pharmaceutical companies. Its strengths lie in specialized areas like recombinant growth hormone and vaccine development, though it faces competition from larger multinational firms with greater R&D budgets and global distribution networks.
Industry Context
Changchun High-Tech Industry (Group) Co., Ltd. operates in Biopharmaceuticals & Pharmaceutical Manufacturing.
Key facts
Founded: 1993 · Headquarters: Changchun, China · Employees: 11,547 · Market cap: ¥52.38B (~$7.2B USD)